Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02564029 · ClinicalTrials.gov registry record · Phase 2

PF-06372865 in Subjects With Photosensitive Epilepsy

A Phase 2 study, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
7
Enrollment target

NCT02564029 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 7 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02564029, a Phase 2 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
7 participants
Enrollment target

Study Summary

PF-06372865 in subjects with photosensitive epilepsy

Interventions

  • DRUG Placebo
  • DRUG Lorazepam
  • DRUG PF-06372865

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2015-12-16
Est. Completion 2017-02-07
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT02564029

The ClinicalTrials.gov registry entry for NCT02564029 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT02564029 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02564029 about?

NCT02564029 is a clinical study titled "PF-06372865 in Subjects With Photosensitive Epilepsy". PF-06372865 in subjects with photosensitive epilepsy

What is the current status of trial NCT02564029?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2015-12-16. Estimated completion is 2017-02-07.

What interventions are being tested in trial NCT02564029?

The interventions under investigation include: Placebo (DRUG), Lorazepam (DRUG), PF-06372865 (DRUG).

Who is sponsoring clinical trial NCT02564029?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.